#Germany #Cologne #Cellex #GMP Facilities #CGT

A Legacy of Innovation and Expansion

Cellex Cell Professionals, a frontrunner in the cell and gene therapy (CGT) manufacturing sector, is proud to celebrate over ten years of remarkable achievements and innovative solutions. Founded in 2001 by Prof. Dr. Gerhard Ehninger in Dresden, Cellex was established with the noble goal of facilitating access to cellular therapies for patients requiring allogeneic blood stem cell transplants. Since its inception, the company has transformed into one of Europe's leading Contract Development and Manufacturing Organizations (CDMO).

With a pivotal expansion occurring in 2009, the company opened a second collection center in Cologne, which resulted in over 50,000 cell collections, subsequently reinforcing its operational capabilities. In 2013, Cellex broadened its service offerings to encompass the entire value chain of CGT, demonstrating its commitment to supporting clients with reliable global transport—amounting to over 20,000 cellular shipments to date.

As part of its ambitious growth strategies, Cellex has undertaken significant expansions to its Good Manufacturing Practice (GMP) infrastructure. Between 2019 and 2025, the company has initiated three major expansions, incorporating high-throughput cleanroom environments and sophisticated quality control laboratories to ensure excellence in production. Today, with over 2,500 m² (over 27,000 ft²) of GMP-certified manufacturing area, Cellex operates with 43% of that space dedicated to cleanroom operations across 37 workstations.

Commitment to Quality and Scalability

Cellex's dedication to high-quality manufacturing is reflected in its impressive track record of over 5,800 CGT/ATMP batches produced, which includes more than 1,300 clinical and over 4,500 commercial products. Notably, the company has successfully manufactured six final drug products and seven cellular intermediates, playing a critical role in the production of three CAR-T therapies that have received approval in the European market. As of 2023, Cellex marked a monumental milestone by producing Europe’s first allogeneic CAR-T product, illustrating the company’s commitment to being at the forefront of therapeutic advancements.

Carla Kreissig, the Managing Director and Chief Medical Officer of Cellex, emphasizes the importance of combining innovation with unparalleled precision and reliability. She notes, “Reaching over 5,800 batches reflects not just scalability but profound process maturity and trust from our partners.”

The recent addition of a new materials warehouse is a testament to this commitment. Designed to the highest industry standards, the facility enhances quality, safety, and efficiency for every batch manufactured, ensuring the company is well-prepared to meet the escalating demand in CGT production.

A Bright Future Ahead

Cellex’s story is not merely one of past successes. The company continues to evolve by onboarding new clients and expanding its operational capabilities. In January 2025, the firm welcomed two new clients, signifying a robust pipeline of projects for the remainder of the year and for years to come. As a trusted partner in the realms of autologous and allogeneic cell therapy, Cellex’s extensive experience positions it uniquely among its European CDMO peers.

About Cellex Cell Professionals

Cellex Cell Professionals is a distinguished full-service CDMO specializing in CGT. With state-of-the-art facilities located in Cologne, Germany, and a proven record of over a decade in GMP-compliant autologous and allogeneic cell therapy manufacturing, Cellex collaborates with numerous prominent pharmaceutical and biotech companies. Its suite of services includes customized starting materials sourced from healthy donors and patients for research, clinical trials, and commercial applications, alongside comprehensive storage and logistics solutions. To learn more about Cellex Cell Professionals and its innovative offerings, visit Cellex's official website.